×
About 30,570 results

ALLMedicine™ Migraine Center

Research & Reviews  9,093 results

The impact of pre-morbid headaches on headache features and long-term health outcomes f...
https://doi.org/10.1111/head.14311
Headache Leibovit-Reiben Z, Ishii R et. al.

May 21st, 2022 - To investigate the impact of having headaches prior to traumatic brain injury (TBI) on headache features and long-term patient health outcomes. This was an exploratory analysis of patients with TBI who were enrolled in the American Registry for Mi...

Long-term efficacy and safety of erenumab in patients with chronic migraine in whom pri...
https://doi.org/10.1111/head.14313
Headache Ashina M, Tepper SJ et. al.

May 21st, 2022 - To assess the long-term efficacy and safety of erenumab in the subgroup of patients with chronic migraine (CM) in whom prior preventive treatments had failed (TF) (≥1, ≥2, and ≥3 TF medication categories) and never failed (preventive naïve or prio...

Migraine and balance impairment: Influence of subdiagnosis, otoneurological function, f...
https://doi.org/10.1111/head.14309
Headache Carvalho GF, Luedtke K et. al.

May 21st, 2022 - To assess the balance sensory organization among patients with migraine, considering the influence of migraine subdiagnosis, otoneurological function, falls, and psychosocial factors. Migraine has been associated with vestibular symptoms and balan...

Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide ins...
https://doi.org/10.1111/head.14304
Headache Zebenholzer K, Gall W et. al.

May 21st, 2022 - To gather information about prescription of triptans and to evaluate whether vascular comorbidity differs in users and nonusers of triptans over the age of 50 years. Beyond the age of 50 years, migraine is still common-yet the incidence of vascula...

see more →

Guidelines  16 results

Guidelines of the International Headache Society for controlled trials of preventive tr...
https://doi.org/10.1177/0333102420941839
Cephalalgia : an International Journal of Headache; Diener HC, Tassorelli C et. al.

Jul 30th, 2020 - Clinical trials are a key component of the evidence base for the treatment of headache disorders. In 1991, the International Headache Society Clinical Trials Standing Committee developed and published the first edition of the Guidelines for Contro...

ACR Appropriateness Criteria® Cerebrovascular Disease-Child.
https://doi.org/10.1016/j.jacr.2020.01.036
Journal of the American College of Radiology : JACR; , Robertson RL et. al.

May 7th, 2020 - Stroke is an uncommon but an important and under-recognized cause of morbidity and mortality in children. Strokes may be due to either brain ischemia or intracranial hemorrhage. Common symptoms of pediatric acute stroke include headache, vomiting,...

Transcranial Magnetic Stimulation for Pain, Headache, and Comorbid Depression: INS-NANS...
https://doi.org/10.1111/ner.13094
Neuromodulation : Journal of the International Neuromodul... Leung A, Shirvalkar P et. al.

Mar 27th, 2020 - While transcranial magnetic stimulation (TMS) has been studied for the treatment of psychiatric disorders, emerging evidence supports its use for pain and headache by stimulating either motor cortex (M1) or dorsolateral prefrontal cortex (DLPFC). ...

Pharmacologic Acute and Preventive Treatment for Migraine in Children and Adolescents.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074018
JAMA Neurology; Szperka CL, VanderPluym JH et. al.

Dec 10th, 2019 - Pharmacologic Acute and Preventive Treatment for Migraine in Children and Adolescents.|2019|Szperka CL,VanderPluym JH,Oakley CB,|prevention & control,

Aids to management of headache disorders in primary care (2nd edition) : on behalf of t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734476
The Journal of Headache and Pain; Steiner TJ, Jensen R et. al.

May 23rd, 2019 - The Aids to Management are a product of the Global Campaign against Headache, a worldwide programme of action conducted in official relations with the World Health Organization. Developed in partnership with the European Headache Federation, they ...

see more →

Drugs  776 results see all →

Clinicaltrials.gov  442 results

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
https://clinicaltrials.gov/ct2/show/NCT04616326

May 20th, 2022 - The study includes a 3-month, randomized, double-blind treatment period in which participants receive either galcanezumab or placebo, followed by a 9-month open-label extension in which all participants receive galcanezumab. Enrollment in the Euro...

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
https://clinicaltrials.gov/ct2/show/NCT03432286

May 20th, 2022 - The study has two parts which enroll separately from each other such that participants may choose to participate in either but not both: the main study and a study addendum. The main study includes a 3-month, randomized, double-blind treatment per...

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
https://clinicaltrials.gov/ct2/show/NCT04396574

May 20th, 2022 - The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
https://clinicaltrials.gov/ct2/show/NCT05028569

May 20th, 2022 - Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (ICHD 2018). Migraine can be further categorized according to the frequency of attacks as epis...

A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
https://clinicaltrials.gov/ct2/show/NCT04458857

May 17th, 2022 - The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of episodic migraine (EM). Secondary objectives are to further demonstrate the efficacy of Fremanezumab as comp...

see more →

News  1,870 results

Safety Concerns with CGRP Monoclonal Antibodies
https://www.mdedge.com/migraine-icymi/article/254294/headache-migraine/safety-concerns-cgrp-monoclonal-antibodies
Lawrence Robbins, MD

May 9th, 2022 - Editors’ note: For the April edition of Expert Perspectives, we asked 2 leading neurologists to present differing views on the use of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) for the treatment of migraine. Here, Lawrence.

Tau Moderated by Menopause; CTE Risk Underestimated; When Is a Single Study Enough?
https://www.medpagetoday.com/neurology/generalneurology/98523

May 3rd, 2022 - Menopause status moderated sex differences in tau burden, with a divergence in tauopathy between the sexes apparent 20 years earlier than previously reported. (Annals of Neurology) Plasma p-tau was a less consistent marker of brain amyloidosis in ...

Roe v. Wade on the Brink; AAP Calls for End to Race-Based Medicine; NYC Cases Climb
https://www.medpagetoday.com/infectiousdisease/covid19/98518

May 3rd, 2022 - Note that some links may require registration or subscription. The Supreme Court has voted to overturn Roe v. Wade, a leaked draft majority opinion obtained by Politico suggests; while not final, it would represent a reversal of abortion rights th...

CGRP mAb vs. standard treatments offer better adherence and persistence in migraine
https://www.mdedge.com/migraine-icymi/article/254088/headache-migraine/cgrp-mab-vs-standard-treatments-offer-better

Apr 25th, 2022 - Key clinical point: Patients with migraine show higher treatment adherence and persistence to calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAb), specifically to galcanezumab, over standard-of-care (SOC) migraine preventive treatme.

Effect of CGRP-receptor mAb therapy resumption after a drug holiday on migraine frequency
https://www.mdedge.com/migraine-icymi/article/254086/headache-migraine/effect-cgrp-receptor-mab-therapy-resumption-after

Apr 25th, 2022 - Key clinical point: Migraine frequency decreases significantly in most patients with migraine on resuming preventive treatment with the same calcitonin gene-related peptide-receptor (CGRP-[R]) monoclonal antibody (mAb) after a 3-month drug holiday.

see more →

Patient Education  31 results see all →